title: Histone H3 lysine 23 acetylation is associated with oncogene TRIM24 expression and a poor prognosis in breast cancer.
abstract: Acetylated H3 lysine 23 (H3K23ac) is a specific histone post-translational modification recognized by oncoprotein TRIM24. However, it is not clear whether H3K23ac levels are correlated with TRIM24 expression and what role H3K23ac may have in cancer. In this study, we collected breast carcinoma samples from 121 patients and conducted immunohistochemistry to determine the levels of TRIM24 and H3K23ac in breast cancer. Our results demonstrated that TRIM24 expression is positively correlated with H3K23ac levels, and high levels of both TRIM24 and H3K23ac predict shorter overall survival of breast cancer patients. We also showed that both TRIM24 and H3K23ac are higher in HER2-positive patients, and their levels were positively correlated with HER2 levels in breast cancer. Moreover, TRIM24 expression is associated with estrogen receptor (ER) and progesterone receptor (PR) statuses in both our cohort and The Cancer Genome Atlas (TCGA) breast carcinoma. In summary, our results revealed an important role of TRIM24 and H3K23ac in breast cancer and provided further evidence that TRIM24 small-molecule inhibitors may benefit ER- and PR-negative or HER2-positive breast cancer patients.
authors.affiliation: Tumor Treatment and Prevention Institute, Harbin Medical University, Baojian Road 6, Nangang District, Harbin, Heilongjiang Province, 150081, China.|Department of Internal Medicine, The Third Affiliated Hospital of Harbin Medical University, Haping Road 6, Nangang District, Harbin, Heilongjiang Province, 150081, China.|Department of Radiation Oncology, The First Hospital Qiqihar City, Qiqihar, China.
authors.forename: Li
authors.initials: L
authors.lastname: Ma
authors.affiliation: Tumor Treatment and Prevention Institute, Harbin Medical University, Baojian Road 6, Nangang District, Harbin, Heilongjiang Province, 150081, China.|Tumor Treatment and Prevention Institute, Heilongjiang Academy of Medical Sciences, Harbin, China.|Key Oncology Laboratory of the Department of Higher Education of Heilongjiang Province, Harbin, China.
authors.forename: Lili
authors.initials: L
authors.lastname: Yuan
authors.affiliation: Tumor Treatment and Prevention Institute, Harbin Medical University, Baojian Road 6, Nangang District, Harbin, Heilongjiang Province, 150081, China.|Tumor Treatment and Prevention Institute, Heilongjiang Academy of Medical Sciences, Harbin, China.|Key Oncology Laboratory of the Department of Higher Education of Heilongjiang Province, Harbin, China.
authors.forename: Jing
authors.initials: J
authors.lastname: An
authors.affiliation: Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Michelle C
authors.initials: MC
authors.lastname: Barton
authors.affiliation: Tumor Treatment and Prevention Institute, Harbin Medical University, Baojian Road 6, Nangang District, Harbin, Heilongjiang Province, 150081, China. zhma19650210@163.com.|Tumor Treatment and Prevention Institute, Heilongjiang Academy of Medical Sciences, Harbin, China. zhma19650210@163.com.|Key Oncology Laboratory of the Department of Higher Education of Heilongjiang Province, Harbin, China. zhma19650210@163.com.|Department of Internal Medicine, The Third Affiliated Hospital of Harbin Medical University, Haping Road 6, Nangang District, Harbin, Heilongjiang Province, 150081, China. zhma19650210@163.com.
authors.forename: Qingyuan
authors.initials: Q
authors.lastname: Zhang
authors.affiliation: Tumor Treatment and Prevention Institute, Harbin Medical University, Baojian Road 6, Nangang District, Harbin, Heilongjiang Province, 150081, China. zliu@hrbmu.edu.cn.|Tumor Treatment and Prevention Institute, Heilongjiang Academy of Medical Sciences, Harbin, China. zliu@hrbmu.edu.cn.|Key Oncology Laboratory of the Department of Higher Education of Heilongjiang Province, Harbin, China. zliu@hrbmu.edu.cn.
authors.forename: Zhaoliang
authors.initials: Z
authors.lastname: Liu
mesh_terms: D000107:Acetylation; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001940:Breast / Q000473:pathology; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology*; D002352:Carrier Proteins / Q000378:metabolism*; D005260:Female; D006657:Histones / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D002352:Carrier Proteins; D006657:Histones; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C555317:TRIM24 protein, human; C508053:ERBB2 protein, human
keywords: Acetylated H3 lysine 23 (H3K23ac); Breast cancer; Prognosis; TRIM24